BioCentury
ARTICLE | Clinical News

Contrave: Phase IV discontinued

April 25, 2016 7:00 AM UTC

Orexigen discontinued the double-blind, placebo-controlled Phase IV CONVENE trial of Contrave following termination of a 2010 deal that granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japa...